276 related articles for article (PubMed ID: 20560860)
21. The use of screening episodes linked to CIN3 and invasive cancer registrations to study outcomes from the NHS Cervical Screening Programme.
Blanks RG; Moss SM; Coleman DA; Addou S; Swerdlow AJ
Cytopathology; 2009 Jun; 20(3):154-60. PubMed ID: 19207309
[TBL] [Abstract][Full Text] [Related]
22. Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial.
Elfström KM; Smelov V; Johansson AL; Eklund C; Nauclér P; Arnheim-Dahlström L; Dillner J
BMJ; 2014 Jan; 348():g130. PubMed ID: 24435414
[TBL] [Abstract][Full Text] [Related]
23. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis.
Sherman ME; Lorincz AT; Scott DR; Wacholder S; Castle PE; Glass AG; Mielzynska-Lohnas I; Rush BB; Schiffman M
J Natl Cancer Inst; 2003 Jan; 95(1):46-52. PubMed ID: 12509400
[TBL] [Abstract][Full Text] [Related]
24. Test positivity cutoff level of a high risk human papillomavirus test could be increased in routine cervical cancer screening.
Kotaniemi-Talonen L; Malila N; Nieminen P; Anttila A; Tarkkanen J; Laurila P; Hakama M
Int J Cancer; 2008 Dec; 123(12):2902-6. PubMed ID: 18792100
[TBL] [Abstract][Full Text] [Related]
25. Three-year risk of high-grade CIN for women aged 30 years or older who undergo baseline Pap cytology and HPV co-screening.
Guo M; Khanna A; Wang J; Dawlett MA; Kologinczak TL; Lyons GR; Bassett RL; Sneige N; Gong Y; Bevers TB
Cancer Cytopathol; 2017 Aug; 125(8):644-651. PubMed ID: 28498639
[TBL] [Abstract][Full Text] [Related]
26. HPV DNA testing in population-based cervical screening (VUSA-Screen study): results and implications.
Rijkaart DC; Berkhof J; van Kemenade FJ; Coupe VM; Rozendaal L; Heideman DA; Verheijen RH; Bulk S; Verweij W; Snijders PJ; Meijer CJ
Br J Cancer; 2012 Feb; 106(5):975-81. PubMed ID: 22251922
[TBL] [Abstract][Full Text] [Related]
27. Cytology versus HPV testing for cervical cancer screening in the general population.
Koliopoulos G; Nyaga VN; Santesso N; Bryant A; Martin-Hirsch PP; Mustafa RA; Schünemann H; Paraskevaidis E; Arbyn M
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD008587. PubMed ID: 28796882
[TBL] [Abstract][Full Text] [Related]
28. Incidence of abnormal cervical and vaginal cytology among women over age 65 years living with human immunodeficiency virus.
Stewart KA; Allen SM; Chesnokova AE; Syed F; Levison JE
Am J Obstet Gynecol; 2020 May; 222(5):486.e1-486.e10. PubMed ID: 31678094
[TBL] [Abstract][Full Text] [Related]
29. Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study.
Kocken M; Helmerhorst TJ; Berkhof J; Louwers JA; Nobbenhuis MA; Bais AG; Hogewoning CJ; Zaal A; Verheijen RH; Snijders PJ; Meijer CJ
Lancet Oncol; 2011 May; 12(5):441-50. PubMed ID: 21530398
[TBL] [Abstract][Full Text] [Related]
30. Risk of invasive cervical cancer after atypical glandular cells in cervical screening: nationwide cohort study.
Wang J; Andrae B; Sundström K; Ström P; Ploner A; Elfström KM; Arnheim-Dahlström L; Dillner J; Sparén P
BMJ; 2016 Feb; 352():i276. PubMed ID: 26869597
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening.
Naucler P; Ryd W; Törnberg S; Strand A; Wadell G; Elfgren K; Rådberg T; Strander B; Forslund O; Hansson BG; Hagmar B; Johansson B; Rylander E; Dillner J
J Natl Cancer Inst; 2009 Jan; 101(2):88-99. PubMed ID: 19141778
[TBL] [Abstract][Full Text] [Related]
32. The performance of human papillomavirus DNA detection with type 16/18 genotyping by hybrid capture in primary test of cervical cancer screening: a cross-sectional study in 10,669 Chinese women.
Zhao X; Wu Q; Wang X; Fu Y; Zhang X; Tian X; Cheng B; Lu B; Yu X; Lan S; Lu W; Ma D; Cheng X; Xie X
Clin Microbiol Infect; 2018 Dec; 24(12):1322-1327. PubMed ID: 29518562
[TBL] [Abstract][Full Text] [Related]
33. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial.
Rijkaart DC; Berkhof J; Rozendaal L; van Kemenade FJ; Bulkmans NW; Heideman DA; Kenter GG; Cuzick J; Snijders PJ; Meijer CJ
Lancet Oncol; 2012 Jan; 13(1):78-88. PubMed ID: 22177579
[TBL] [Abstract][Full Text] [Related]
34. Primary cervical cancer screening with an HPV mRNA test: a prospective cohort study.
Sørbye SW; Fismen S; Gutteberg TJ; Mortensen ES; Skjeldestad FE
BMJ Open; 2016 Aug; 6(8):e011981. PubMed ID: 27515759
[TBL] [Abstract][Full Text] [Related]
35. Recent increase in incidence of cervical precancerous lesions in Norway: Nationwide study from 1992 to 2016.
Orumaa M; Leinonen MK; Campbell S; Møller B; Myklebust TÅ; Nygård M
Int J Cancer; 2019 Nov; 145(10):2629-2638. PubMed ID: 30734284
[TBL] [Abstract][Full Text] [Related]
36. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
[TBL] [Abstract][Full Text] [Related]
37. Screening for cervical intraepithelial neoplasia in north east Scotland shows fall in incidence and mortality from invasive cancer with concomitant rise in preinvasive disease.
Macgregor JE; Campbell MK; Mann EM; Swanson KY
BMJ; 1994 May; 308(6941):1407-11. PubMed ID: 8019250
[TBL] [Abstract][Full Text] [Related]
38. The IMproving Primary Screening And Colposcopy Triage trial: human papillomavirus, cervical cytology, and histopathologic results from the baseline and 1-year follow-up phase.
Safaeian M; Wright TC; Stoler MH; Ranger-Moore J; Rehm S; Aslam S; Fang Q; Volkir P; Ridder R
Am J Obstet Gynecol; 2021 Sep; 225(3):278.e1-278.e16. PubMed ID: 33852886
[TBL] [Abstract][Full Text] [Related]
39. Invasive cervical cancer audit: why cancers developed in a high-risk population with an organised screening programme.
Herbert A; Anshu ; Culora G; Dunsmore H; Gupta SS; Holdsworth G; Kubba AA; McLean E; Sim J; Raju KS
BJOG; 2010 May; 117(6):736-45. PubMed ID: 20184570
[TBL] [Abstract][Full Text] [Related]
40. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial.
Bulkmans NW; Berkhof J; Rozendaal L; van Kemenade FJ; Boeke AJ; Bulk S; Voorhorst FJ; Verheijen RH; van Groningen K; Boon ME; Ruitinga W; van Ballegooijen M; Snijders PJ; Meijer CJ
Lancet; 2007 Nov; 370(9601):1764-72. PubMed ID: 17919718
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
